预约演示

更新于：2025-05-16

Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

更新于：2025-05-16

概要

概要

基本信息

药物类型

预防性疫苗

别名

Circumsporozoite protein hepatitis-B surface antigen fusion protein- GlaxoSmithKline、CSP-HBsAg - GlaxoSmithKlineCSP-HBsAg - GlaxoSmithKline、CSP-HBsAg/SBAS2-GlaxoSmithKline

+ [27]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

权益机构-

最高研发阶段批准上市

首次获批日期

比利时 (2015-01-10),

恶性疟

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 126827

关联

项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的临床试验

PACTR202503849420187

/ Suspended临床2期

A Phase 2a, open label, randomized, interventional study to assess the safety and immunogenicity of alternative vaccination regimens and reduced antigen doses of RTS,S/AS01E vaccine in healthy children aged 5-60 months in a malaria-endemic area

开始日期2025-06-02

申办/合作机构

GlaxoSmithKline Biologicals SA

PACTR202409856142141

/ SuspendedN/AIIT

Evaluating antibody responses longitudinally and correlation to clinical malaria in children who received seasonal vaccination with RTS,S/AS01E with and without seasonal malaria chemoprevention in Mali.

开始日期2024-10-01

申办/合作机构-

NCT06424002

/ Not yet recruiting临床4期IIT

The Impact, Feasibility Acceptability and Cost Effectiveness of the RTS,S/AS01 Malaria Vaccine in School Aged Children

Across sub-Saharan Africa, school-age children bear an under-appreciated burden of malaria. An estimated 200 million school-age children are at risk of malaria and in many areas prevalence of infection exceeds 50%. The high infection rates in this group serves as a source of onward parasite transmission, undermining elimination and control efforts. Furthermore, malaria illness and malaria-induced anemia in this age group lead to school absenteeism, and impaired cognitive function and classroom attention, ultimately resulting in reduced academic achievement. Although universal malaria interventions, such as insecticide treated nets (ITNs) and access to prompt diagnosis and treatment are available to school-age children, this age group is the least likely to benefit from these interventions. Furthermore, efficacy of these approaches may be compromised by increasing anti-malarial drug and insecticide resistance. A malaria vaccine could help to avert the burden of malaria in this age group.
The RTS,S/AS01 malaria vaccine has recently been recommended for vaccination of young children (< 24 months) by the World health organization (WHO) after a Phase 3 trial and an implementation trial showed that the vaccine had moderate but significant efficacy to prevent clinical and severe malaria in young children. Previous randomized trials suggest that the vaccine is safe for older children. However, efficacy of the vaccine has never been assessed in school age children. Kamuzu University of Health Sciences in partnership with the Malawian Ministry of Health seeks to evaluate the efficacy of the newly introduced RTSS/AS01 malaria vaccine in school aged children. The study hypothesizes that vaccination will decrease the morbidity and transmission of malaria, as well as improve school absenteeism and educational outcomes.

开始日期2024-06-01

申办/合作机构

Michigan State University

[+2]

100 项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的临床结果

登录后查看更多信息

100 项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的转化医学

登录后查看更多信息

100 项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的专利（医药）

登录后查看更多信息

468

项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的文献（医药）

2025-05-01·Lancet Global Health

Incidence rates of malaria, meningitis, and mortality in children younger than 5 years: a prospective cohort study in Ghana and Kenya before the roll-out of the RTS,S/AS01E malaria vaccine from 2016 to 2022

Article

作者: Oguk, Esther ; Awuni, Dennis Azabra ; Harrison, Samuel Bernard Ekow ; Cravcenco, Cristina ; Haine, Valérie ; Oyieko, Janet ; Kaali, Seyram ; Agyapong, Prince Darko ; Sing'oei, Valentine ; Ansah, Nana Akosua ; Kaburise, Michael Bandasua ; Asante, Kwaku Poku ; Otieno, Walter ; Owusu-Agyei, Seth ; Boahen, Owusu ; Kayan, Kingsley ; Roman, François ; Schuerman, Lode ; Otieno, Lucas ; Dosoo, David ; Ansah, Patrick Odum ; Bozonnat, Marie-Cécile ; Adeniji, Elisha ; Tivura, Mathilda ; Savic, Miloje

BACKGROUND:

The RTS,S/AS01_E malaria vaccine was introduced in selected communities of Ghana, Kenya, and Malawi in 2019 under a WHO-coordinated pilot programme. The scarcity of background disease incidence rates might hamper the assessment of vaccine safety and effectiveness. We aimed to determine the incidence rates of malaria, meningitis, and death, and health outcomes leading to hospital admission in children younger than 5 years enrolled before RTS,S/AS01_E implementation. Interim results from EPI-MAL-002 up to Oct 5, 2018, were reported previously. Here, we report results from the final analysis of the pre-vaccine introduction study.

METHODS:

This disease surveillance study combined two approaches: (1) prospective cohort event monitoring (home visits scheduled to mimic a future four-dose RTS,S/AS01_E vaccination schedule [ie, a simulated vaccination schedule], with additional visits after the simulated schedule and continuous disease monitoring of outpatient visits and hospital admission) in children enrolled in two age groups (6-12 weeks [6-12W] and 5-17 months [5-17M]), and (2) hospital-based disease surveillance for children not enrolled in the prospective cohort, in three sites in Ghana and Kenya. Key outcomes were rates of meningitis, malaria, adverse events of special interest, other adverse events leading to hospital admission, all-cause mortality, and malaria-attributable mortality.

FINDINGS:

The final analysis included 23 427 children: 9032 in the 6-12W age group, 9694 in the 5-17M age group, and 4701 in hospital-based disease surveillance. In the 5-17M age group (corresponding to the WHO-recommended age for RTS,S/AS01_E vaccination), the incidence rates of meningitis and cerebral malaria within an at-risk period of 1 year after the simulated vaccination schedule were both equal to 28 (95% CI 9-65) per 100 000 person-years. There were 11 (0·1%) children with an adverse event of special interest during hospital admission. In the 5-17M age group, the all-cause mortality rate was 643 (95% CI 531-771) per 100 000 person-years.

INTERPRETATION:

Observed incidence of meningitis and cerebral malaria were in the previously published range, whereas childhood mortality was lower, suggesting that the recent efforts to reduce mortality in children younger than 5 years have been impactful. Data from this study have public health use and will form the baseline evidence for ongoing evaluation of the benefit-risk of RTS,S/AS01_E.

FUNDING:

GSK and PATH.

2025-04-01·Lancet Global Health

Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study

Article

作者: Mzanga, Phylis ; Owusu-Agyei, Seth ; Onyango, Irene ; Nyangulu, Wongani ; Okoth, George Odhiambo ; Kaali, Seyram ; Ababio, Lucy Osei ; Sifuna, Peter M ; Cherop, Reuben Yego ; Roman, François ; Jere, Tikhala Makhaza ; Awuni, Denis ; Orsini, Mattea ; Maleta, Kenneth ; Otieno, Walter ; Kaburise, Michael Bandasua ; Adeniji, Elisha ; Haine, Valérie ; Amoit, Stellah Kevyne ; Guerra Mendoza, Yolanda ; Phiri, Vincent Katunga ; Odera-Ojwang, Patricia ; Oneko, Martina ; Oyieko, Janet Nyawira ; Ochieng, Benard Omondi ; Chipatala, Raphael ; Orimbo, John ; Kariuki, Simon ; Debois, Muriel ; Kayan, Kingsley ; Cravcenco, Cristina ; Harrison, Samuel B E ; Asante, Kwaku Poku ; Olewe, Fredrick ; Sing'oei, Valentine ; Agyapong, Prince Darko ; Savic, Miloje ; Ansah, Nana Akosua ; Boahen, Owusu ; Schuerman, Lode ; Mategula, Donnie ; Ogutu, Bernhards ; Achieng Oguk, Esther ; Devadiga, Raghavendra ; Azongo, Daniel K ; French, Neil ; Ansah, Patrick Odum ; Ndeketa, Latif ; Ong'echa, John Michael ; Oduro, Abraham Rexford

BACKGROUND:

RTS,S/AS01_E has been successfully administered to over two million children since 2019 through the Malaria Vaccine Implementation Programme (MVIP). In this Article, we report the safety results of a study evaluating RTS,S/AS01_E safety and effectiveness in real-world settings.

METHODS:

EPI-MAL-003 is an ongoing phase 4 disease surveillance study with prospective cohort event monitoring and hospital-based surveillance, done in the setting of routine health-care practice in Ghana, Kenya, and Malawi and fully embedded in the MVIP. The study design was dependent on the cluster-randomised vaccine implementation. In active surveillance, we enrolled children younger than 18 months from exposed (where RTS,S/AS01_E was offered) and unexposed clusters. The coprimary endpoints were the occurrence of predefined adverse events of special interest and aetiology-confirmed meningitis. We report primary and secondary safety results up to 1 year after the primary vaccine schedule (three doses). The study is registered with ClinicalTrials.gov, NCT03855995.

FINDINGS:

The first participant was enrolled on March 21, 2019. The cutoff date for the current analysis was 1 year after the third RTS,S/AS01_E dose for each participant. In total, 44 912 children (19 993 in Ghana, 11 990 in Kenya, and 12 929 in Malawi) were included in the analysis set for the cluster-randomised comparison: 22 508 from exposed clusters and 22 404 from unexposed clusters. Incidence rates (expressed per 100 000 person-years) for generalised convulsive seizures and intussusception were similar between vaccinated and unvaccinated children. Aetiology-confirmed meningitis was reported in two children: one case of bacterial meningitis due to Streptococcus pneumoniae in an RTS,S/AS01_E-vaccinated child in the exposed clusters, and one case of viral meningitis due to human herpesvirus 6 in an unvaccinated child in the unexposed clusters. Both cases occurred within 12 months after vaccination in children in the cluster-design analysis set, leading to incidence rates of 4·1 (95% CI 0·1-23·0) per 100 000 person-years in RTS,S/AS01_E-vaccinated children and 4·0 (0·1-22·6) per 100 000 person-years in unvaccinated children, and a country-adjusted incidence rate ratio (IRR) of 0·96 (95% CI 0·06-15·34; p=0·98). Cerebral malaria cases were reported for four (<0·1%) of 20 639 RTS,S/AS01_E-vaccinated children in the exposed clusters and two (<0·1%) of 22 137 unvaccinated children in the unexposed clusters. These included three and two cases occurring within 12 months after the primary vaccination, in RTS,S/AS01_E-vaccinated children and unvaccinated children, respectively (IRR 1·43, 95% CI 0·24-8·58, p=0·70). Incidence rates for all-cause mortality were 659·7 (95% CI 561·5-770·3) in vaccinated children versus 724·5 (622·3-838·8) in unvaccinated children, with similar incidence rates for boys and girls.

INTERPRETATION:

We found no evidence of vaccination being associated with an increased risk of meningitis, cerebral malaria, or mortality among vaccinated children, and no new safety risks were identified.

FUNDING:

GSK.

2025-04-01·VACCINE

Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy

Article

作者: Gupta, Dinesh ; Singh, Susheel K ; Kumar, Dhiraj ; Mohmmed, Asif ; Khan, Summaiya ; Junaid, Iqbal Taliy ; Arkam, Shaikh Zikra ; Singh, Agam P ; Verma, Sheenam ; Salunke, Dinakar M ; Ahmad, Shahnawaz ; Parveen, Sadaf ; Tabrez, Shams ; Theisen, Michael ; Malhotra, Pawan ; Rath, Pragyan Parimita ; Singh, Pooja

Developing an effective vaccine against malaria remains a prime goal of human health. The circumsporozoite protein (CSP) is a major surface protein of the sporozoites, and is the target of two licensed Plasmodium falciparum malaria vaccines, RTS,S/AS01, named Mosquirix and R21/Matrix-M. However, to improve the standards set by these vaccines we require a second-generation or prophylactic vaccine. Recently, monoclonal antibodies have emerged as essential biopharmaceutical prophylactic vaccines. The present study targeted recombinant Plasmodium falciparum CSP (rPfCSP) with a phage display of human single-fold scFv Tomlinson libraries I+J and picked fourteen scFvs that represented two independent clones after sequencing; CL1 and CL3. These phages were analysed for their binding to rPfCSP. The selected scFvs were cloned in a human IgG1 Fc tag vector, to generate scFv-Fc full-length antibody clones. CL1 bound rPfCSP protein with a K_D of 3.8x10^-6M and CL3 bound rPfCSP protein with a K_D of 5.6 x 10^-5 M. These antibodies detected native PfCSP on the sporozoite surface. Molecular docking simulation revealed that rPfCSP residues interacting with CL1 and CL3 were downstream of the repeat region. These antibodies inhibited the sporozoite infectivity into HepG2 cells, similar to a gold standard monoclonal antibody, 2A10. Low-dose passive transfer of the CL1 and CL3 antibodies conferred high-level protection when challenged with PfCSP-Pb transgenic parasites in the mouse infection model. The high in vitro and in vivo efficacies of the CL1 and CL3 antibodies have applications in malaria immunoprophylaxis in protecting travellers and military servicemen or as a therapeutic vaccine in malaria elimination programmes.

项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的新闻（医药）

2025-04-22

·药时代

近160亿：生物医药行业3月融资规模再破记录

今年3月，美国及欧洲的生物医药行业共发生18起融资事件，融资规模达21.8亿美元（约158.96亿人民币），其中值得关注的有：AI制药领域大额融资集中爆发：3月，位居融资额前两位均是AI制药公司，其中，诺奖得主创立的Isomorphic Labs更是单轮完成创纪录的6亿美元融资；前沿技术路线与新靶点受到关注：3月，HDAC6抑制剂公司Augustine 、mGluR5负变构调节剂公司Tempero Bio、KnotBody药物公司Maxion Therapeutics等前沿技术公司均获得大额融资。1、Isomorphic Labs：诺奖得主创办的AI药企3月31日，Isomorphic Labs宣布在第一轮外部融资中筹集了6亿美元。本轮融资由Thrive Capital领投，GV、Alphabet提供后续资金。此次领投的Thrive Capital是如今全球最为炙手可热的风险投资机构之一，以“在少数初创企业押下巨额赌注”的风格著称，曾投出过OpenAI、Instagram、Stripe、Spotify等一众明星项目。Isomorphic Labs成立于2021年，创始人兼CEO为2024年诺贝尔化学奖得主Demis Hassabis。公司致力于利用人工智能技术重新定义药物发现和开发流程，其核心技术包括AlphaFold等革命性AI模型。此前木头姐的《Big Ideas 2025》报告中，将Isomorphic Labs列为AI药物研发领域的少数关键公司。AlphaFold是一种能够预测蛋白质三维结构的AI模型，将预测误差从传统方法的10Å级别压缩至原子尺度（1.6Å）。基于AlphaFold的技术基础，Isomorphic Labs开发了PhoenixAI平台，该平台通过图神经网络（GNN）与扩散模型（Diffusion Model）的融合架构，能够模拟药物分子与蛋白质口袋的原子级相互作用，显著缩短了先导化合物优化周期。2024年5月，Isomorphic Labs与谷歌DeepMind共同开发的AlphaFold 3模型发布，能够准确预测所有生命分子的结构和相互作用，能够显著降低新药研发成本，并提高临床成功率。据摩根士丹利预测，该技术若完全落地，可将新药研发成本从当前平均26亿美元压缩至1.7亿美元，同时将临床成功率从9.6%提升至34%。公司优异的技术，斩获了多家大药企的合作，合作金额高达30亿美元：2024年1月7日，Isomorphic Labs宣布与礼来达成战略研究合作，合作开发针对多个靶点的小分子疗法，公司将获得4500万美元的预付现金，以及潜在高达17亿美元的里程碑付款和净销售额高达两位数的分成；2024年1月7日，Isomorphic Labs宣布与诺华达成战略研究合作，合作开发针对三个未公开靶点的小分子疗法。公司获得3750万美元的预付款，以及潜在高达12亿美元的里程碑付款和从中单到低两位数的净销售额的分成；除了这些合作伙伴关系外，Isomorphic 还在推进多个治疗领域和药物模式的设计项目，包括肿瘤、自身免疫疾病等。公司计划今年年底前将一些人工智能设计的药物投入临床试验。公司的科学顾问委员会包括2020年诺贝尔化学奖获得者、CRISPR先驱 Jennifer Doudna，2021年诺贝尔化学奖获得者David MacMillan，2001年诺贝尔生理学或医学奖得 Paul Nurse，以及阿斯利康前执行副总裁Mene Pangalos等知名人士。近年来，AI制药是资本市场追逐的热点，包括Retro Biosciences（10亿美元A轮）、Xaira Therapeutics（10亿美元初始资金）、EvolutionaryScale（1.42 亿美元种子轮）在内的多家AI制药企业近期获得或正在筹集巨额早期融资。2、Lila Sciences：Flagship Pioneering孵化的AI药物公司3月10日，Lila Sciences宣布完成2亿美元的种子轮融资。本轮融资投资人包括Flagship Pioneering、General Catalyst、March capital、ARK Venture Fund、Altitude Life Science Ventures、Blue Horizon Advisors、State of Michigan Retirement System、Modi Ventures和阿布扎比投资局（ADIA）等知名机构。Lila Science于2023年诞生在Flagship内部实验室。当时，Flagship孵化了两家早期AI公司：一家专注于新材料，另一家专注于生物学，后来两家公司的发展目标趋于一致，招募相同的人才，因此在内部合并。Lila Science致力于在开发一款人工智能程序，该程序经过已发表的实验数据以及科学过程推理的训练。仅仅两年时间，公司平台已在多个领域表现出超越人类和现有人工智能基准的性能，例如：生成优于市售疗法的最佳基因药物结构、发现和验证数百种适用于广泛治疗靶点的新型抗体、肽和结合剂、设计用于工业规模碳捕获的新材料等。在商业模式上，Lila并未像其他AI制药公司那样自己直接下场研发新药，而是与Flagship孵化药企、外部生物技术公司合作，承担 “科研助推器”的角色，加快同行药物研发速度。团队方面，Lila Science集聚了业内众多知名专家：哈佛大学著名遗传学家 George Church担任首席科学家、OpenAI前高管Kenneth Stanley担任高级副总裁、Flagship的普通合伙人Geoffrey von Maltzahn 担任首席执行官。3、Callio Therapeutics：Frazier Life Sciences孵化的ADC药物公司3月3日，Callio Therapeutics宣布完成1.87亿美元的A轮融资。本轮融资由Frazier Life Sciences领投，Jeito Capital、Novo Holdings A/S、Omega Funds、ClavystBio、Platanus、Norwest、Pureos Bioventures、SEEDS Capital和EDBI等知名机构跟投。Callio Therapeutics是一家由Frazier Life Sciences孵化设立的ADC药物公司，致力于开发下一代多载荷ADC。公司的ADC采用差异化的有效载荷和接头技术，能够将多载荷靶向递送至肿瘤细胞，从而最大限度地提高治疗效果。Callio Therapeutics的管线与技术来自Hummingbird Bioscience的授权。公司获得了后者双plyload技术平台、以及两个ADC管线的独家授权。其中一个较快的管线为靶向Her2双payload ADC，第二个管线尚未披露靶点。而Hummingbird则获得Callio的股权，以及两个授权管线的未来里程碑付款。Hummingbird的ADC技术来自著名的ADC技术平台公司Synaffix：2023年1月，Hummingbird以1.5亿美元总额获得了Synaffix三大平台技术GlycoConnect™、HydraSpace™、ToxSYN™的授权。公司的首个项目是靶向HER2的双有效载荷ADC：HMBD-802。根据公司在2024年AACR大会上的介绍，HMBD-802的两个payload分别为拓扑异构酶Ⅰ抑制剂和ATR抑制剂，用以克服单一Topo1i ADC的耐药性。公司联合创始人兼CEOPiers Ingram此前曾是Hummingbird Bioscience的联合创始人，亦曾在此前在赛诺菲等医药企业从事了15年的研发咨询、商业战略和学术工作。首席医疗官Naomi曾担任ProfoundBio（普方生物）的首席医疗官（被Genmab以18亿美元收购），在此之前，她曾担任Silverback Therapeutics的首席医疗官、Acerta Pharma的临床开发和医疗事务副总裁、Seattle Genetics的临床开发副总裁等职务。4、Latigo Biotherapeutics：Vertex镇痛药的潜在挑战者3月17日，Latigo Biotherapeutics宣布完成1.5亿美元的B轮融资，本轮融资由Blue Owl Capital管理的基金领投，卡塔尔投资局、Deep Track Capital、Access Biotechnology、Cormorant Asset Management、赛诺菲风险投资公司、Rock Springs Capital、UPMC Enterprises、Kern Capital、Westlake Village BioPartners、Foresite Capital、5AM Ventures和Alexandria Venture Investments等机构跟投。Latigo Biotherapeutics由生物医药投资机构Westlake Village BioPartners于2020年孵化设立，是一家专注于开发非阿片类止痛药的生物技术公司。目前，公司有四款在研药物，其中最为主要的是LTG-001。这是一款口服选择性Nav1.8抑制剂，目前正在进行临床二期试验，旨在治疗急性和慢性疼痛，预计今年下半年发布数据。NaV 1.8抑制剂为近几年走进医药行业视野的全新机制镇痛药，具有起效快、疗效显著、安全性优于标准护理且不影响中枢神经系统等潜在优势。今年1月底，Vertex Pharmaceuticals旗下药物Journavx成功获批，成为首个获得FDA批准针对 NaV1.8 的止痛药物。虽说Journavx面临着一定程度的商业挑战，疼痛缓解市场一直被廉价的阿片类药物“霸占”，但分析师们还是相当看好药物前景，预测它能够跻身十亿美元药物。Latigo的LTG-001有可能成为有望成为“best-in-class”药物。除了LTG-001，公司还有一系列Nav1.8抑制剂，正处于发现阶段。Westlake运营合伙人Desmond Padhi博士为公司首席执行官。在加入Westlake之前，Padhi博士在安进（Amgen）工作了20年，曾担任药代动力学、药物代谢和临床药理学副总裁一职。在一级市场，2024年2月，Latigo Biotheraputics宣布完成1.35亿美元的A轮融资，本轮融资由Westlake Village BioPartners领投，5AM Ventures和Foresite Capital，Corner Ventures参与跟投。公司的孵化机构Westlake Village BioPartners成立于2018年，致力于与有望为患者带来变革性疗法的企业家共同培育、发展生命科学公司。Westlake的联合创始人Sean Harper博士于2002年进入安进研发部门，并于2012年成为研发执行副总裁，期间领导安进心血管疾病、肿瘤学、神经科学和肾脏疾病领域药物的新品获批。5、Curevo Vaccine：带状疱疹疫苗Shingrix的挑战者3月17日，Curevo Vaccine宣布完成1.1亿美元的B轮融资。本轮融资由Medicxi领投，OrbiMed、HBM Healthcare Investments、赛诺菲风险投资公司、RA Capital Management、Janus Henderson investors、Adjuvant Capital和GC Biopharma等机构跟投。Curevo Vaccine创立于2018年，是一家专注于生产新一代带状疱疹疫苗的药企。公司唯一的管线CRV-101是一款佐剂亚单位疫苗，用于预防老年人带状疱疹。CRV-101被专门设计为在使用少量佐剂的同时产生最佳免疫应答，目的是获得与目前批准的带状疱疹疫苗相似的疗效，但副作用较少。目前，已经上市的带状疱疹疫苗有默沙东的减毒活疫苗Zostavax、以及葛兰素史克的基因重组亚单位疫苗Shingrix。其中，Shingrix凭借90%的有效率，占据市场主导地位。2024年1月7日，公司宣布CRV-101疫苗在对随机、对照、观察者盲法各组的临床二期试验达到了主要终点。CRV-101有效性为100%，而Shingrix为97.9%。此外，CRV-101较Shingrix相比表现出更低的局部或全身不良反应发生率。为了将Shingrix彻底比下去，公司还在进行多达640人的扩展试验，旨在确定临床三期的剂量选择。管理层方面，公司董事会主席Moncef Slaoui博士曾在葛兰素史克工作了近30年，期间为许多新疫苗的开发做出了贡献，包括Shingrix®（带状疱疹）、Cervarix®（HPV诱导的宫颈癌疫苗）、Mosquirix®（疟疾）、Rotarix®）（轮状病毒肠胃炎）和Synflorix®。另外一位董事Tal Zaks 博士在Moderna担任首席医疗官超过六年，期间还负责监督COVID-19的mRNA疫苗Spikevax的开发。在一级市场，公司曾完成两轮融资：2022 年2月，Curevo Vaccine宣布完成6000万美元A轮融资。本轮融资由RA Capital牵头，Aduvant Capital、Janus Henderson investors、EN Investment和创始投资者GC Pharma跟投；2022年11月，Curevo Vaccine宣布完成2600万美元A+轮融资，投资人包括Janus Henderson、RA Capital 、Adverant Capital和GC Biopharma。6、Character Biosciences：博士伦支持的眼科新药公司3月25日，Character Biosciences宣布完成1亿美元的C轮融资。本轮融资由aMoon和Luma Group共同领投，博士伦、Jefferson Life Sciences、Innovation Endeavors、Catalio Capital、S32和KdT Ventures等机构跟投。Character Biosciences成立于2019年，致力于采用资金效率更高的观察性研究来构建患者数据库并开拓多基因疾病的精准医疗解决方案。通过与全美150多家眼科中心合作，公司构建了一个涵盖6500多名患者的基因-临床-影像数据库，实现了AMD的遗传亚型重分类，并以此发现关键致病机制和靶点，结合AI与多组学方法，有望提升复杂眼病精准治疗的成功率。目前，公司有四个在研管线，其中最为重要的有：CTX114：一款补体抑制剂，旨在减缓晚期干性AMD的地图样萎缩的进展。药物设计用于抑制补体系统激活，保护视网膜细胞表面免受免疫攻击；CTX203：一款脂质调节剂，适应症为高风险中期AMD。该药为人工设计的ApoA1类似肽，针对ABCA1脂质转运通道，具有“延缓进展”而非“逆转疾病”的作用方向，定位于尚无药物覆盖的中早期AMD人群（尚未发展至地形萎缩）。CTX203与CTX114预计将于今年进入临床试验阶段。该公司还利用其人工智能驱动的基于基因组学的平台，将其产品线扩展到其他眼科疾病。对外合作方面，2024年1月，公司宣布与博士伦签署协议，共同开发针对AMD的治疗方法，并可能将双方的合作扩展至其他眼科疾病领域。公司创始人兼CEO Cheng Zhang先生拥有丰富的跨行业经验，曾在多家知名公司担任重要职务。在瑞银（UBS）、Oliver Wyman和辉瑞等公司任职期间，他积累了宝贵的战略规划和创新管理经验，参与并推动了多项战略计划的实施。7、Augustine Therapeutics：礼来支持的HDAC6抑制剂药企3月24日，Augustine Therapeutics宣布完成8480万美元的A轮融资。本轮融资由Novo Holdings和Jeito Capital共同领投，Asabys Partners、礼来、AdBio Partners、V-Bio Ventures、PMV、VIB、Gemma Frisius Fund、Charcot Marie Tooth（CMT）研究基金会、Newton Biocapital等机构跟投。Augustine Therapeutics成立于2019年，由比利时弗拉芒生物技术研究所（VIB）与鲁汶大学（KU Leuven）的联合孵化，致力于解决目前缺乏有效治疗方案的重大医疗需求，包括腓骨肌萎缩征等影响周围神经的遗传性疾病，以及其他神经肌肉、神经退行性和心脏代谢性疾病。公司的科学基础源于VIB-KU鲁汶脑与疾病研究中心的Ludo Van Den Bosch教授在胞浆组蛋白脱乙酰酶6（HDAC6）抑制方面的突破性研究，他认为HDAC6抑制剂是治疗CMT和其他神经疾病的有前景的方法。HDAC6是一种II类组蛋白脱酰酶。HDAC6是一种众所周知的分子靶点，对神经系统疾病有很强的生物学基础，对心脏代谢疾病有很高的治疗潜力。2023年，诺华以8000万美元获得了韩国公司Chong Kun Dang Pharmaceutical的1期阶段的HDAC6抑制剂CKD-510。目前，Augustine Therapeutics正在开发HDAC6的同类最佳的小分子抑制剂，适应症为Charcot-Marie Tooth（CMT）。CMT是最常见的外周神经系统遗传性疾病，影响全球约300万人。一级市场，Augustine最初由V-Bio Ventures、AdBio Partners、VIB、PMV和Gemma Frisius Fund组成并提供种子资金，并于2024年6月完成1850万美元的A轮融资，投资人包括Asabys Partners、礼来、Charcot Marie Tooth研究基金会等机构。8、Arbor Biotechnologies：张峰的又一家基因编辑公司3月18日，Arbor Biotechnologies宣布完成7390万美元的C轮融资。本轮融资由ARCH Venture Partners和TCGX领投，QIA、abrdn、Partners Investment、Revolution Partners、Kerna Ventures、Ally Bridge、Arrowmark、Deep Track、Piper Heartland Healthcare、Surveyor、淡马锡、T.Rowe Price Associates和Vertex制药等机构跟投。Arbor Biotechnologies成立于2016年，是一家基因编辑酶开发公司。Arbor联合创始人包括张锋教授、David Walt、David Scott、Winston Yan等业内知名人士。Arbor主要是通过机器学习与人工智能技术来开发新的基因编辑器，截至目前，公司已拥有17种基因编辑器，覆盖90%以上的基因组。还发现了超60多种核酸酶家族和70多种CRISPR转座酶，数量是已发表文献中的6倍和30倍。Arbor的基因编辑器主要包括两大类：CRISPR核酸酶编辑器、CRISPR转座酶编辑器。其中CRISPR核酸酶包括DNA核酸酶（Cas12h，Cas12i）和RNA核酸酶（Cas13d，Cas12g，III-E型）等。2024年5月，Arbor还收购了张锋旗下另一家基因编辑公司Serendipity Biosciences，获得了DNA核酸内切酶基因编辑器Fanzor、基因编辑器IsrB等技术。目前，公司有在研管线8款，最为重要的是ABO-101。ABO-101是一种针对原发性高草酸尿症（PH）的体内基因编辑疗法，于2024年12月获得了FDA的IND批准，目前正在PH1中进行临床I/II期试验，预计2029年初步完成。此前，在2024 ASGCT年会上，Arbor公布了BO-101的临床前数据。在非人灵长类动物（NHP）中，BO-101对HAO1基因实现了有效的体内编辑，多次给药具有良好的耐受性。此外，公司还在推进其首个同类项目的IND/CTA备案，包括一个罕见肝病的RT（逆转录酶）编辑项目和一个针对肌萎缩侧索硬化症（ALS）的项目。对外合作方面，Vertex是公司的长期合作伙伴，于2018年首次达成合作，并于2021年和2023年两次扩大合作协议，尤其是2021年的扩展合作金额高达12亿美元。此外，Arbor分别在2022年和2024年Allogene与博雅辑因达成了授权合作。在一级市场，公司曾完成两轮融资：2017年5月，Arbor宣布完成560万美元A轮融资后走出隐匿模式；2021年11月，Arbor宣布完成2.15亿美元的B轮融资。本轮融资由淡马锡、汇桥资本和TCG Crossover领投，Arrowmark、Deep Track、Great Point Ventures、Illumina Ventures、Janus Henderson investors、Logos Capital、Ono Venture、Piper Heartland Healthcare、Ridgeback Capital、Section 32、Surveyor Capital、T.Rowe Price Associates、Tao等机构跟投。图片来源：123RF版权声明/免责声明本文为授权转载文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢!药时代官方网站:www.drugtimes.cn联系方式:电话:13651980212微信:27674131邮箱:contact@drugtimes.cn点击这里，查看更多精彩!

引进/卖出

2025-03-18

·GlobeNewswire-Health Care

Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine

-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures -- Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair March 17, 2025 -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles. Leading the round is new investor Medicxi, a European biotech-focused investment firm with significant experience investing in vaccine companies such as Vaxcyte and ViceBio. Joining Medicxi is an international group of investment funds including OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Capital Management, Janus Henderson Investors, Adjuvant Capital, and founding investor GC Biopharma. “This Series B round will fund the extension of our successful Phase 2 program into an additional 640 participants, including the key population of adults over age 70, to finalize dose selection ahead of the Phase 3 program,” said Curevo’s CEO, George Simeon, MBA/MPH. “Designed based upon feedback from regulators and other stakeholders, this short extension trial will begin mid-2025 and serve to set the company for clinical, strategic, and regulatory success.” Concurrent with the round, Moncef Slaoui, PhD, will join Curevo as Board Chair. Dr. Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed during the COVID-19 pandemic, helping deliver vaccines against the SARS-CoV-2 virus. He spent nearly 30 years at GlaxoSmithKline, during which he helped shape its vaccine business by contributing to the creation of numerous new vaccines including Shingrix® (shingles), Cervarix® (HPV-induced cervical cancer), Mosquirix® (malaria), Rotarix® (rotavirus gastroenteritis), and Synflorix® (pneumococcal disease). “I have been collaborating with the Curevo team for several weeks now,” stated Dr. Slaoui. “I’m very excited to work with them to help perfect shingles vaccination, adding good tolerability to the exceptional efficacy achieved by the current vaccine. The data so far show Curevo’s adjuvant technology has the attributes to succeed in this endeavor.” Also joining Curevo’s Board of Directors will be Giovanni Mariggi, PhD, co-founder and Partner at Medicxi, an experienced infectious disease investor and board member. “Patients, doctors, and payors are very clear a new shingles vaccine like amezosvatein would be welcome in the global marketplace. Amezosvatein’s activity and improved tolerability profile could allow it to be a significant product in the shingles vaccines market. We are excited to support Curevo’s plan with a streamlined path to approval,” stated Dr. Mariggi. Tal Zaks, MD/PhD, will be joining Curevo’s Board of Directors on behalf of OrbiMed. Dr. Zaks is the former Chief Medical Officer of Moderna, where he led development of their mRNA vaccine against the SARS-CoV-2 virus. He previously held senior leadership positions in drug development at GSK and Sanofi. “OrbiMed has a long history of investing in biotech companies like Curevo seeking to improve healthcare outcomes while creating long-term shareholder value,” said Dr. Zaks. “The fact amezosvatein contains an optimized version of the TLR4 agonist with a known mechanism of action reduces biological risk while providing the competitive advantage of potentially improved tolerability, which should position it as the first choice for people who want to be protected from shingles.” ‘Amezosvatein’ is the assigned non-proprietary name for CRV-101, a non-mRNA adjuvanted subunit vaccine under investigation by Curevo. Like Shingrix, amezosvatein uses a subunit protein antigen called glycoprotein ‘E’ (gE). Targeting the gE antigen is proven to elicit a long-term, protective immune response to prevent shingles. Amezosvatein’s adjuvant contains an optimized version of the TLR4 agonist proven by Shingrix to be biologically active in shingles vaccination. Amezosvatein was engineered to maintain exceptional efficacy and have a best-in-class tolerability profile. The SLA-SE adjuvant formulation was developed at Seattle-based Access to Advanced Health Institute (AAHI) and amezosvatein was licensed from the Mogam Institute for Biomedical Research, a research institute funded by South Korea’s GC Biopharma. Curevo is a privately held, clinical-stage biotechnology company based near Seattle dedicated to reducing the burden of infectious disease by developing vaccines with improved tolerability and accessibility. Curevo’s lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain. The current $4+ billion shingles vaccine market is characterized by accessibility issues and vaccine hesitancy/dose avoidance related to vaccine tolerability. For more information visit https://curevovaccine.com/. Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need. For more information, please visit: https://www.medicxi.com. OrbiMed is a leading global healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, via private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets. For more information, please visit www.orbimed.com. Switzerland-based HBM Healthcare Investments focuses on the healthcare sector, holding and managing an international portfolio of promising companies in the human medicine, biotechnology, medical technology, diagnostics, and related areas. Many of these companies have their lead products already available on the market or are at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (SIX:HBMN). Sanofi Ventures is the corporate venture capital arm of Sanofi, focused on investing in promising early-stage healthcare companies. The firm supports pioneering innovations in biotechnology, digital health, and life sciences aligning with Sanofi’s mission to bring life-changing treatments to patients worldwide. For more information, please visit www.sanofiventures.com. Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital's knowledge engine is guided by its TechAtlas internal research division, and Raven, RA Capital's healthcare incubator, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re-imagined. RA Capital has more than 150 employees and over $10 billion in assets under management. Janus Henderson Investors exists to help clients achieve their long-term financial goals. Its active management offers clients the opportunity to outperform passive portfolios over the course of market cycles. With more than 360 investment professionals, Janus Henderson Investors provides access to some of the industry’s most talented and innovative thinkers, spanning equities, fixed income, multi-asset, and alternatives, globally. Its investment teams blend insight, originality, and precision with rigorous analysis, structured processes, and robust risk management. Janus Henderson Investors builds client partnerships on openness and trust, channeling expertise from across the business and communicating the views of its experts in a timely and relevant way. https://www.janushenderson.com/ Headquartered in New York, with offices in Zürich, Adjuvant is a global life science investment fund built to accelerate the development of new technologies for the world's most pressing public health challenges. Backed by prominent healthcare and emerging market investors, Adjuvant draws upon its network of scientists, public health experts, biopharmaceutical industry veterans, and development finance professionals to identify new investment opportunities. Adjuvant invests in companies developing promising new vaccines, therapeutics, diagnostics, and medical devices targeting high-burden infectious diseases, maternal and child health, antimicrobial resistance, and malnutrition, with a commitment to make these interventions accessible globally. For more information, visit http://www.adjuvantcapital.com Founding investor GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yongin, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines and expanded its global presence with the successful USA market entry of ALYGLO™ (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platforms to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit https://www.gcbiopharma.com/eng/ The content above comes from the network. if any infringement, please contact us to modify.

疫苗

2025-02-04

·ir.arcturusrx.com

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

SAN DIEGO --(BUSINESS WIRE)--Feb. 4, 2025-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui , Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company’s Board of Directors since June 2024 . “Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate,” said Joseph Payne , President & Chief Executive Officer of Arcturus. “We look forward to working with him as we enter a transformative year of advancing our pipeline of therapeutics and vaccines.” “Arcturus has deep expertise in mRNA delivery for therapeutics and a validated commercial stage vaccines platform,” said Dr. Moncef Slaoui . “I am excited to work with the company during this potentially transformational time with multiple key data readouts across its pipeline.” About Dr. Moncef Slaoui Dr. Moncef Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed. Under his leadership the operation enabled the fastest ever development, manufacturing, and approval of multiple COVID-19 vaccines in less than 11 months after the virus genetic sequence was described. Dr. Slaoui has sat on several biotechnology company boards, including Moderna, Inc. and Lonza Group AG , and he chaired the boards of Galvani, and Vaxcyte, a vaccine development platform company. Dr. Slaoui spent nearly 30 years at GlaxoSmithKline (GSK) holding leadership positions including as member of the Board of Directors of GSK PLC; Chairman of Pharmaceutical R&D; Chairman Global R&D, Vaccines & Oncology; and Chairman, Global Vaccines. As Chairman of Pharmaceutical R&D, Dr. Slaoui led a redesign of GSK’s R&D structure and culture to improve focus on innovation and productivity. As Chairman of Global Vaccines, Dr. Slaoui was directly involved in GSK's vaccine pipeline, leading to the creation of 14 new vaccines, including Shingrix®, to prevent shingles; Cervarix®, to prevent cervical cancer; Mosquirix, to prevent malaria; Rotarix®, to prevent rotavirus gastroenteritis; and Synflorix, to prevent pneumococcal disease. In 2016, Dr. Slaoui was recognized as one of Fortune's 50 Greatest World Leaders for his work in under-researched diseases common in the developing world. He served on the Advisory Committee to the Director of the NIH from 2011 to 2016 and has advised the U.S. President's Council of Advisors on Science and Technology . Dr. Slaoui holds a Ph.D. in Molecular Biology and Immunology from the Université Libre de Bruxelles , completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine , and was a Professor of Immunology at the University of Mons , Belgium . He received an accelerated Master of Business Administration from IMD, Switzerland in 1998. About Arcturus Founded in 2013 and based in San Diego, California , Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan , ARCALIS , focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S. , Europe , Japan , China , and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20250204663825/en/ Arcturus Therapeutics Public Relations & Investor Relations Neda Safarzadeh VP, Head of IR/PR/Marketing (858) 900-2682 IR@ArcturusRx.com Source: Arcturus Therapeutics Holdings Inc.

疫苗高管变更信使RNA

100 项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07X	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
恶性疟	比利时	GSK Plc	2015-01-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
麻疹	临床3期	加纳	GSK Plc	2017-05-10
风疹	临床3期	加纳	GSK Plc	2017-05-10
黄热病	临床3期	加纳	GSK Plc	2017-05-10
乙型肝炎	临床3期	布基纳法索	GSK Plc	2011-11-17
乙型肝炎	临床3期	加纳	GSK Plc	2011-11-17
HIV感染	临床3期	肯尼亚	GSK Plc	2010-07-30
疟疾	临床3期	布基纳法索	GSK Plc	2009-03-27
疟疾	临床3期	加蓬	GSK Plc	2009-03-27
疟疾	临床3期	加纳	GSK Plc	2009-03-27
疟疾	临床3期	肯尼亚	GSK Plc	2009-03-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04661579 (CTgov)	临床2期	恶性疟	620	Dihydroartemisinin-piperaquine (DHA/Pip)+Artemether / Lumefantrine+Primaquine+Malaria Vaccine RTS,S/AS01E (Group 1: Positive Parasitemia; Anti-malarial Treatment + RTS,S/AS01E Vaccine)	齋網齋夢壓鏇壓選觸繭 = 積簾鏇夢鹽觸鏇鏇構齋範襯襯鹽遞膚鬱獵獵遞 (範構鏇憲憲餘淵觸艱顧, 艱遞鬱膚鬱鹹艱壓衊糧 ~ 築構構鏇糧廠窪選選糧) 更多	-	2024-07-19
				Abhayrab rabies vaccine+Dihydroartemisinin-piperaquine (DHA/Pip)+Artemether / Lumefantrine+Primaquine (Group 4: Positive Parasitemia; Anti-malarial Treatment + Rabies Vaccine)	齋網齋夢壓鏇壓選觸繭 = 鹽鹹遞獵簾鹽顧艱構襯範襯襯鹽遞膚鬱獵獵遞 (範構鏇憲憲餘淵觸艱顧, 網廠鏇鹽憲鹽衊夢憲築 ~ 醖鏇製構遞繭壓蓋構憲) 更多
NCT03276962 (CTgov)	临床2期	疟疾	1,500	S+RTS,S/AS01E (Full dose) (Fx012-14-mFxD Group)	獵製蓋襯壓鏇遞壓築鹽 = 築蓋艱積衊製選鹽積壓艱鏇艱積鹹構願壓繭願 (鏇餘衊簾壓醖憲鹽願膚, 蓋構餘鹹顧膚壓鏇獵簾 ~ 積鹽膚獵衊範範構製餘) 更多	-	2024-05-21
				RTS,S/AS01E (Full dose) (R012-20 Group)	鏇蓋夢築淵鏇夢蓋壓構 = 糧淵鬱獵構構鬱鹹餘艱壓齋遞顧鏇艱膚淵獵顧 (鹽願鬱憲艱範窪衊遞願, 壓糧憲構餘簾壓夢構衊 ~ 積鬱齋艱夢餘壓鏇遞餘) 更多
NCT03162614 (Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults, Pubmed \| J Infect Dis)	临床2期	疟疾 Plasmodium falciparum-infected mosquito challenge	130	RTS,S/AS01B three-dose regimen	餘窪窪窪築選遞鬱顧鑰(構繭憲蓋夢鏇襯遞獵積) = 築糧觸窪遞鑰衊鏇糧膚齋壓艱蓋製窪範繭築簾 (襯選襯範膚願遞願繭願, 27 ~ 72)	积极	2020-10-13
				RTS,S/AS01E three-dose regimen	餘窪窪窪築選遞鬱顧鑰(構繭憲蓋夢鏇襯遞獵積) = 窪築醖鏇繭憲憲築艱獵齋壓艱蓋製窪範繭築簾 (襯選襯範膚願遞願繭願, 48 ~ 89)
NCT02699099 (CTgov)	临床3期	黄热病 \| 疟疾 \| 风疹 ... 更多	699	Vitamin A+Stamaril+MR-Vac+Candidate Plasmodium falciparum malaria vaccine (Coad Group)	鏇願觸鑰選遞網夢遞構(衊簾繭願蓋憲製夢遞願) = 蓋遞壓鏇蓋襯襯構夢憲鏇鏇繭膚鑰膚鏇簾憲膚 (壓餘觸鹽選憲餘糧艱膚, 壓壓膚淵簾選鹽選遞鏇 ~ 鑰積製醖壓鑰艱簾選選) 更多	-	2019-08-29
				Vitamin A+Stamaril+MR-Vac+Candidate Plasmodium falciparum malaria vaccine (RTS,S Group)	鏇願觸鑰選遞網夢遞構(衊簾繭願蓋憲製夢遞願) = 鹽鹹簾膚夢簾獵繭夢艱鏇鏇繭膚鑰膚鏇簾憲膚 (壓餘觸鹽選憲餘糧艱膚, 鑰遞願簾窪鹽襯壓衊壓 ~ 糧鹹遞簾範築範繭選鏇) 更多
NCT02207816 (CTgov)	临床3期	疟疾	3,084	Blood sampling+Polio Sabin Oral Polio Vaccine+Malaria Vaccine 257049 (MALARIA-055 PRI) (GSK257049 Group)	憲顧襯願醖淵鑰網窪廠(淵鑰獵鑰範淵醖觸淵糧) = 鏇願網鏇憲願選膚壓窪獵鹹鹹鹹觸窪構鑰積衊 (醖蓋構淵夢製鹹餘鑰鹹, 鬱壓願構衊簾積膚遞齋 ~ 積襯蓋顧夢鹽憲廠淵艱) 更多	-	2019-08-15
				Blood sampling+Malaria Vaccine 257049 (MALARIA-055 PRI) (GSK257049 Comparator Group)	憲顧襯願醖淵鑰網窪廠(淵鑰獵鑰範淵醖觸淵糧) = 選壓構艱範顧製網鬱壓獵鹹鹹鹹觸窪構鑰積衊 (醖蓋構淵夢製鹹餘鑰鹹, 鏇選窪繭範築觸壓鹽蓋 ~ 醖遞憲鑰齋範構築網淵) 更多
NCT02992119 (RTSS, CTgov)	临床2期	疟疾	193	S+AS01B+RTS (Group 1)	製顧鹹鹽製襯遞願築蓋 = 繭膚襯壓襯醖積構淵範選糧遞願鹹鹹範範築築 (鹹齋餘製衊製積窪獵衊, 艱積淵獵遞鹹網齋餘顧 ~ 觸鑰觸簾繭選願鑰齋蓋) 更多	-	2019-07-29
				Double RTS,S/AS01E Fractional dose (Group 2)	製顧鹹鹽製襯遞願築蓋 = 範壓壓範製膚醖觸齋餘選糧遞願鹹鹹範範築築 (鹹齋餘製衊製積窪獵衊, 鹹選願遞積鏇壓蓋衊蓋 ~ 鬱膚衊壓範淵衊壓鹹遞) 更多
NCT03162614 (Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults, CTgov)	临床2期	疟疾	154	Sporozoite-infected mosquitoes challenge.+RTS,S/AS01B (AduFx Group)	齋鏇廠憲襯憲餘築憲選 = 觸選繭鹹遞齋選繭遞蓋構壓積築願淵襯願繭壓 (顧鏇鹽淵鹽選窪淵鹽夢, 艱願蓋範壓糧鬱蓋鑰鑰 ~ 艱鹹襯選鹽鑰選簾構衊) 更多	-	2019-07-24
				Sporozoite-infected mosquitoes challenge.+RTS,S/AS01E (2PedFx Group)	齋鏇廠憲襯憲餘築憲選 = 觸構夢齋繭繭觸壓積製構壓積築願淵襯願繭壓 (顧鏇鹽淵鹽選窪淵鹽夢, 鹹願鬱積蓋選憲艱範夢 ~ 鏇積顧築鬱齋網醖壓窪) 更多
NCT01148459 (CTgov)	临床3期	疟疾 \| HIV感染	200	GSK257049 vaccine (GSK257049 Group)	鬱齋簾製鑰糧網觸製膚 = 衊製鏇憲艱簾蓋鏇鑰鹽糧願鹽構淵淵壓構顧夢 (齋願醖窪鬱衊顧獵糧餘, 齋鑰鏇鏇夢築糧窪淵醖 ~ 繭淵積製選遞網廠積網) 更多	-	2019-01-16
				Verorab (Verorab Group)	鬱齋簾製鑰糧網觸製膚 = 積範獵網構遞艱鹽築淵糧願鹽構淵淵壓構顧夢 (齋願醖窪鬱衊顧獵糧餘, 顧構積顧糧醖膚簾遞鹽 ~ 鬱網襯顧襯衊顧製築繭) 更多
NCT00380393 (RTS,S/AS01E, CTgov)	临床2期	恶性疟	894	GSK malaria vaccine 257049 Vaccine (GSK257049 Group)	選醖齋窪積觸壓餘襯窪 = 夢鹽餘鹽淵選願衊鹹築餘鏇蓋襯鏇獵鬱鹽衊醖 (餘築廠顧齋壓窪網構醖, 繭壓鏇鏇壓積餘選網顧 ~ 網壓艱築膚顧夢衊鑰獵) 更多	-	2018-07-03
				Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine (Rabipur Group)	選醖齋窪積觸壓餘襯窪 = 構鹽淵廠艱鑰餘餘憲積餘鏇蓋襯鏇獵鬱鹽衊醖 (餘築廠顧齋壓窪網構醖, 鑰繭積糧獵積膚網糧醖 ~ 膚構築齋憲糧範鹹簾醖) 更多
NCT00360230 (CTgov)	临床2期	疟疾	540	GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 (SB257049 F2 0-1 M Group)	夢選鏇簾製遞簾糧艱願 = 構糧鏇範窪顧艱構構構糧範衊廠齋鬱繭壓齋鑰 (壓選鏇繭壓夢構繭艱觸, 窪構憲製艱構鹹鑰願構 ~ 遞構鹹鬱醖選觸窪夢襯) 更多	-	2018-02-19
				GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 (SB257049 F1 0-1 M Group)	夢選鏇簾製遞簾糧艱願 = 鹽淵遞膚繭艱蓋壓觸簾糧範衊廠齋鬱繭壓齋鑰 (壓選鏇繭壓夢構繭艱觸, 製糧醖製鏇襯衊齋構願 ~ 構膚艱醖襯衊艱願觸積) 更多